** Lipella Pharmaceuticals' shares rise 7% to $2.59 premarket
** LIPO says completed dosing of first group of patients in mid-stage study of LP-310, its key experimental drug to treat oral lichen planus
** OLP is a chronic inflammatory disease that affects mucous membranes inside the mouth
** Disease affects about 6-7 million Americans, and has no approved drug besides those used to alleviate symptoms, the co's website says
** As of last close, stock had fallen 70% YTD
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments